Whole-genome sequencing targets drug-resistant bacterial infections
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
During the past two decades, the technological progress of whole-genome sequencing (WGS) had changed the fields of Environmental Microbiology and Biotechnology, and, currently, is changing the underlying principles, approaches, and fundamentals of Public Health, Epidemiology, Health Economics, and national productivity. Today's WGS technologies are able to compete with conventional techniques in cost, speed, accuracy, and resolution for day-to-day control of infectious diseases and outbreaks in clinical laboratories and in long-term epidemiological investigations. WGS gives rise to an exciting future direction for personalized Genomic Epidemiology. One of the most vital and growing public health problems is the emerging and re-emerging of multidrug-resistant (MDR) bacterial infections in the communities and healthcare settings, reinforced by a decline in antimicrobial drug discovery. In recent years, retrospective analysis provided by WGS has had a great impact on the identification and tracking of MDR microorganisms in hospitals and communities. The obtained genomic data are also important for developing novel easy-to-use diagnostic assays for clinics, as well as for antibiotic and therapeutic development at both the personal and population levels. At present, this technology has been successfully applied as an addendum to the real-time diagnostic methods currently used in clinical laboratories. However, the significance of WGS for public health may increase if: (a) unified and user-friendly bioinformatics toolsets for easy data interpretation and management are established, and (b) standards for data validation and verification are developed. Herein, we review the current and future impact of this technology on diagnosis, prevention, treatment, and control of MDR infectious bacteria in clinics and on the global scale.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global trends in emerging infectious diseases
Jones, K. E., Patel, N. G., Levy, M. A., Storeygard, A., Balk, D., Gittleman, J. L., & Daszak, P. (2008) · Nature · doi:10.1038/nature06536 · Cited by 8,338
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Identification of acquired antimicrobial resistance genes
Zankari, E., Hasman, H., Cosentino, S., Vestergaard, M., Rasmussen, S., Lund, O., Aarestrup, F. M., & Larsen, M. V. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks261 · Cited by 4,980 · cited 1×
“The housekeeping, structural, and functional genes and intergenic regions [11, 30, 53, 77, 95, 126, 136, 140, 142, 156, 168, 195, 203, 260], as well as the virulent and resistance factors are considered as clinically important markers and are applicable for benchtop typing [206].”
BackgroundDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512 · cited 1×
“Unfortunately, most inhibitors identified in highthroughput screenings are not active against live bacteria or are not safe for use in humans [185].”
BackgroundA Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“, bedaquiline, pyridomycin, SQ109, BM212, adamantyl ureas, benzimidazole, BTZ, TCA, and imidazol[1,2-a]pyridine related derivatives) succeeded by a combination of high-throughput screening and WGS analysis of spontaneous resistant mutants for target identification, combined with modern bioinformatics tools [8, 97, 183…”
BackgroundThe Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices
Jorgensen, J. H., & Ferraro, M. J. (2009) · Clinical Infectious Diseases · doi:10.1086/647952 · Cited by 1,894
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Cited by
Whole-Genome Sequencing for Detecting Antimicrobial Resistance in Nontyphoidal Salmonella
McDermott, P. F., Tyson, G. H., Kabera, C., Chen, Y., Li, C., Folster, J. P., Ayers, S. L., Lam, C., Tate, H. P., & Zhao, S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01030-16 · Cited by 376
Bacterial Vaginosis: Current Diagnostic Avenues and Future Opportunities
Redelinghuys, M. J., Geldenhuys, J., Jung, H., & Kock, M. M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00354 · Cited by 167
He, S., Leanse, L. G., & Feng, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113922 · Cited by 141
Bioinformatic Methodologies in Assessing Gut Microbiota
Fox, J. D., Sims, A., Ross, M., Bettag, J., Wilder, A., Natrop, D., Borsotti, A., Kolli, S., Mehta, S., Verma, H., et al. (2024) · Microbiology Research · doi:10.3390/microbiolres15040170 · Cited by 15
Metadata
- Authors
- Punina, N. V., Makridakis, N. M., Remnev, M. A., & Topunov, A. F.
- Venue
- Human Genomics
- Published
- 2015-08-05
- Volume
- 9
- Issue
- 1
- Pages
- 19-19
- ISSN
- 1473-9542 (ISSN-L)
- 1479-7364
- OpenAlex
- W2159361332
- Cited by
- 110
- References
- 20
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Whole-genome sequencing targets drug-resistant bacterial infections. https://app.cochat.ai/papers/10.1186/s40246-015-0037-z
- The paper
- Punina, N. V., Makridakis, N. M., Remnev, M. A., & Topunov, A. F. (2015). Whole-genome sequencing targets drug-resistant bacterial infections. Human Genomics. https://doi.org/10.1186/s40246-015-0037-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.